PASSReviewer 1· 80% conf
Reporting is largely complete: methods are detailed, the trial is registered, limitations are discussed, and conclusions are proportional. No reporting guideline (CONSORT) is referenced, and the trial is not prospectively registered in a WHO primary registry.
Evidence
paraphrase[Methods, Standard protocol approvals, registrations and patient consents]
“The study is registered with ClinicalTrials.gov (NCT04492020).”paraphrase[Discussion, Limitations, paragraph 1]
“Paraphrase: The authors note the trial was not designed to evaluate prodrom kinainitan effect on prodromal symptoms; these were prespecified additional endpoints analyzed outside the hierarchical gatekeeping, so not controlled for multiple comparisons; and that participants dosed at the onset of confidence rather than at first recognition of prodromal symptoms.”paraphrase[Discussion, final paragraph]
“Reversing these symptoms with a gepant emphasizes the importance of the brain in migraine and offers the promethe Dwight possibility that targeting central nervous system mechanisms will be a fruitful path to new therapeutics in this common and disabling disorder.”PASSReviewer 2· 90% conf
The manuscript is transparent with detailed methods, trial registration, limitations, and funding/COI statements.
Evidence
direct quote[Methods, Standard protocol approvals, registration and patient consents]
“The study is registered with ClinicalTrials.gov ( NCT04492020 (https://clinicaltrials.gov/ct2/show/NCT04492020) ).”direct quote[Discussion, Limitations]
“These analyses were outside the hierarchical gatekeeping procedure to control for type-1 error and were therefore not controlled for multiple comparisons.”direct quote[Acknowledgements; Competing interests]
“AbbVie funded the present study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing and approval of the publication.”